Springfield, MO

Log in Subscribe

Novartis bets $9.7B on cholesterol drug

Posted online

Novartis AG penned a $9.7 billion purchase deal for Medicines Co.

Bloomberg reports the acquisition focuses mostly on a single treatment: experimental cholesterol drug inclisiran.

Similarly, last year Novartis gained muscle disease gene therapy Zolgensma by buying drugmaker AveXis Inc. for $8.7 billion.

Read more from Bloomberg.


No comments on this story |
Please log in to add your comment
Editors' Pick
Open for Business: Finley River Chiropractic

Adrianna Norris became a first-time business owner with the opening of Finley River Chiropractic; PaPPo’s Pizzeria & Pub launched its newest location; and Huey Magoo’s opened its second store in the Ozarks.

Most Read
Update cookies preferences